Cargando…

Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy

BACKGROUND: Our previous study showed that SLC22A18 downregulation and promoter methylation were associated with the development and progression of glioma and the elevated expression of SLC22A18 was found to increase the sensitivity of glioma U251 cells to the anticancer drug 1,3-bis(2-chloroethyl)-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Sheng-Hua, Ma, Yan-Bin, Feng, Dong-Fu, Li, Zhi-Qiang, Jiang, Pu-Cha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3610152/ https://www.ncbi.nlm.nih.gov/pubmed/23514245 http://dx.doi.org/10.1186/1479-5876-11-69

Ejemplares similares

Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma
por: Chu, Sheng-Hua, et al.
Publicado: (2011)

Aspergillosis in a Patient Receiving Temozolomide for the Treatment of Glioblastoma
por: Munhoz, Rodrigo Ramella, et al.
Publicado: (2013)

Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide
por: Topkan, Erkan, et al.
Publicado: (2022)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide
por: Sun, Stella, et al.
Publicado: (2012)

Retraction: Receptor tyrosine kinase AXL is correlated with poor prognosis and induces temozolomide resistance in glioblastoma
por: Wang, Jia, et al.
Publicado: (2019)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation
por: Liu, Yu-Jie, et al.
Publicado: (2017)

Cost-Effectiveness of [(18)F] Fluoroethyl-L-Tyrosine for Temozolomide Therapy Assessment in Patients With Glioblastoma
por: Baguet, Tristan, et al.
Publicado: (2019)

Value of [(18)F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab
por: Graham, Maya S, et al.
Publicado: (2020)

RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma
por: Chen, Yunping, et al.
Publicado: (2023)

Metformin treatment reduces temozolomide resistance of glioblastoma cells
por: Yang, Seung Ho, et al.
Publicado: (2016)

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma
por: Gong, Lingli, et al.
Publicado: (2022)

Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma
por: Ward, Sarah M., et al.
Publicado: (2018)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
por: Kim, Hyungsin, et al.
Publicado: (2019)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

Early Assessment of the Efficacy of Temozolomide Chemotherapy in Experimental Glioblastoma Using [(18)F]FLT-PET Imaging
por: Viel, Thomas, et al.
Publicado: (2013)

Glutathione S-Transferase M3 Is Associated with Glycolysis in Intrinsic Temozolomide-Resistant Glioblastoma Multiforme Cells
por: Cheng, Shu-Yu, et al.
Publicado: (2021)

Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients
por: Wang, Yu, et al.
Publicado: (2017)

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021)

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-Analysis
por: Yin, An-an, et al.
Publicado: (2013)

Upregulation of SATB1 is associated with the development and progression of glioma
por: Chu, Sheng-Hua, et al.
Publicado: (2012)

The Roles of Imprinted SLC22A18 and SLC22A18AS Gene Overexpression Caused by Promoter CpG Island Hypomethylation as Diagnostic and Prognostic Biomarkers for Non-Small Cell Lung Cancer Patients
por: Noguera-Uclés, José Francisco, et al.
Publicado: (2020)

Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres
por: Kim, Hee Yeon, et al.
Publicado: (2019)

Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling
por: Zhang, Xiao-Ning, et al.
Publicado: (2021)

Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines
por: Sun, Stella, et al.
Publicado: (2011)

Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer
por: Jung, Yeonjoo, et al.
Publicado: (2015)

Relation between autophagy and the resistence of glioblastoma cells to temozolomide
por: Carmo, Anália, et al.
Publicado: (2010)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
por: Stepanenko, Aleksei A., et al.
Publicado: (2016)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
por: He, Yang, et al.
Publicado: (2019)

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
por: Singh, Neha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k89gcn7prm77ctpnqjs93ebj4e